Beijing Winsunny Pharmaceutical CO.LTD (601089) — Capital Reinvestment Ratio
Beijing Winsunny Pharmaceutical CO.LTD (601089) has a Capital Reinvestment Ratio of 0.57x as of December 2024, meaning it reinvests 1% of its operating cash flow (CN¥690.75 Million) in capital expenditures (CN¥391.52 Million). Check 601089 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Beijing Winsunny Pharmaceutical CO.LTD Capital Reinvestment Ratio (2020–2024)
This chart tracks Beijing Winsunny Pharmaceutical CO.LTD's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see 601089 cash flow conversion.
Annual Capital Reinvestment Ratio for Beijing Winsunny Pharmaceutical CO.LTD (2020–2024)
Year-by-year Capital Reinvestment Ratio for Beijing Winsunny Pharmaceutical CO.LTD from 2020 to 2024. See 601089 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.57x | CN¥690.75 Million | CN¥391.52 Million | ▼ -13.9% |
| 2023 | 0.66x | CN¥555.90 Million | CN¥366.08 Million | ▲ +220.9% |
| 2022 | 0.21x | CN¥659.76 Million | CN¥135.40 Million | ▼ -43.8% |
| 2021 | 0.37x | CN¥528.02 Million | CN¥192.97 Million | ▼ -16.4% |
| 2020 | 0.44x | CN¥386.65 Million | CN¥168.96 Million | — |